Bold Moves

Deliver first-in-class science

Transform our go-to-market model

In support of Pfizer’s five-point COVID-19 plan, Pfizer Global Supply colleagues in McPherson, Kansas, are manufacturing remdesivir for Gilead Sciences

Part of Pfizer’s five-point plan to address COVID-19 includes our commitment to using any excess manufacturing capacity and to potentially shifting production to support other companies’ efforts to expand the supply of investigational treatments for the disease.

That’s why Pfizer Global Supply colleagues in McPherson, Kansas, are manufacturing remdesivir for Gilead Sciences through Pfizer CentreOne, a global contract development and manufacturing organization embedded within Pfizer and a leading supplier of specialty active pharmaceutical ingredients.

“As the entire world continues to battle COVID-19, I am so proud of how our colleagues worked efficiently and collaboratively, demonstrating our Pfizer values of courage and excellence,” said Ian MacKellar, McPherson Site Leader. “This effort required both decisive decision-making and unrelenting attention to detail to help ensure safety, quality and compliance requirements were met under an accelerated timeframe. Our entire team has been honored to work with Gilead on this important endeavor to impact patients’ lives at such a critical time in our history.”

The project went from kickoff to the shipment of the first lot to Gilead in just four months. We couldn’t have achieved this timeline without our highly engaged and committed project team, who worked with dedication and commitment to meet our project deliverables."


Lynn Goering

Senior Manager, Project Management, Pfizer

The McPherson team shipped the first clinical batch of remdesivir to Gilead ahead of the original target, as part of this new partnership that colleagues find “motivating and rewarding.”

“As Pfizer colleagues, we impact patients’ lives every day, but with this project, there was a heightened awareness of the need and ability to really make a difference,” said Lynn Goering, Senior Manager, Project Management. 

Discover more

Advances for a Potential First-in-Class Chronic OA Pain Treatment

Advancing Breakthroughs for Patients With NASH

Eucrisa, Now Starring Jessica Simpson

Working for Patients with Alopecia Areata

Advancing a Potential Breakthrough for Moderate to Severe Atopic Dermatitis

A Potentially Practice-Changing Approval in Advanced Urothelial Cancer

Addressing an Unmet Need for Certain Patients With BRAF-Mutant mCRC

Learning From Early Breast Cancer Studies to Drive Oncology Research Forward

Cancer Doesn’t Wait: Supporting Screenings During COVID-19

Positive Phase 1/2 Data at One Year for Hemophilia A Gene Therapy

Investigational Gene Therapy for Duchenne Muscular Dystrophy Achieves Exciting Milestones in 2020

Pfizer Vaccines Pipeline Includes Six Late-Stage Candidates

Pfizer Vaccines Launches​​​​​​​ Global Centers of Excellence Network

Progressing Maternal Vaccination Against Respiratory Syncytial Virus

Pfizer Pledges $100 Million Into New AMR Industry Fund

Partnering with Wellcome to Combat AMR in Sub-Saharan Africa

Expanding Access in China Through Health Insurance Innovation

Pfizer Invests in Biotechnology Innovation through the Pfizer Breakthrough Growth Initiative

Hospital Donations for COVID-19 Response

Pfizer Partners with BioNTech to Advance & Supply COVID-19 Vaccine​​​​​​​

Delivering on the Promise of Biosimilars

Driving Diversity in Our Research and Development​​​​​​​

Site Feature: Puurs, Belgium 

PGS Ingenuity Solves COVID-19 Cold Chain Storage Challenge​​​​​​​

Pfizer and Gilead Sciences Agree to Manufacture and Supply Remdesivir​​​​​​​

Key Medicine Supply and Public Policy During COVID-19

Pfizer Stands with Science

Five-Point Plan for Unprecedented Collaboration

COVID-19 Updates

Read the latest information about Pfizer’s COVID-19 vaccine on



Join the Conversation

Additional Information

Useful Links

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

Copyright © 2020-2021 Pfizer Inc.
All rights reserved

Explore our stories